Primary Biliary Cholangitis, previously known as Primary Biliary Cirrhosis, is a rare disease, which mainly affects women in their fifth to seventh decades of life. It is a chronic autoimmune disease characterized by a progressive damage of interlobular bile ducts leading to ductopenia, chronic cholestasis and bile acids retention. Even if the disease usually presents a long asymptomatic phase and a slow progression, in many patients it may progress faster toward cirrhosis and its complications. The 10 year mortality is greater than in diseases such as human immunodeficiency virus/Hepatitis C Virus coinfection and breast cancer. 
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Introduction
As its prevalence is below 5 cases out of 10,000, Primary Biliary Cholangitis (PBC) is a rare disease according to the European Union criteria. Its former denomination, Primary Biliary Cirrhosis, was changed into Primary Biliary Cholangitis, leaving the PBC abbreviation unaffected, in the year 2015. The change of nomenclature was made to address the demands from patient organizations and providers in the sector so as to remove the term cirrhosis, which only refers to the end stage of the disease. Indeed, as of today, PBC is generally diagnosed in the earlier phases of the disease and treatments are often capable of blocking progression. For this reason, labeling PBC patients as cirrhotic was frustrating and incoherent as well [1] . 4 PBC is a chronic autoimmune disease electively affecting interlobular bile ducts (cholangitis) leading to retention of bile salts into the liver (cholestasis) and secondary damage of hepatocytes. The onset is often silent and insidious but the disease may progress toward cirrhosis, liver failure and death.
As PBC is a rare disease, the issues related to it concern, among others, diagnosis, care and shared management of the patient not only by specialized centers but also in the local outpatient healthcare setting.
To study this rare condition there has been an international effort to build up a network on centres studying PBC. The Global PBC Group, an international independent working group, was established in 2012 with the aim of setting up a collaboration among centers involved in the scientific research program on PBC.
All data collected from patients followed by these centers are merged into a single database which accounts for more than 6,000 patients as of today [2] .
The present document is the outcome of the consensus reached within an Italian working group of experts on the disease (physicians, pharmacologists and patients) and its purpose is to establish shared recommendations with regard to disease management and treatment for the benefit of the providers of the sector.
Epidemiology: according to the latest estimates, patients affected by PBC range from 12 to 13,000 in Italy.
Global PBC prevalence and incidence provided in the latest Orphanet report are 2.1/10,000 and 0.3/10,000/year, respectively [3] . Two revisions of the 5 epidemiological studies conducted in various geographical regions, North America (US and Canada), Northern Europe (Norway, Finland, Sweden, Denmark and UK), Spain, Israel and Australia, were published in 2012 and 2013 [4, 5] , showing a marked variability of epidemiological data among the different regions, with prevalence ranging from 0.09 to 4.02/10,000 and incidence ranging from 0.03 to 0.58/10,000/year. As discussed by the authors, such variability is likely due to the varying degree of access to diagnosis and care rather than an actual geographic difference in the epidemiology of the disease.
No specific PBC register is currently in place in Italy. According to the only PBC typically affects women aged from 50 to 60 years old [7] [8] [9] . The silent form of PBC is characterized by positivity of anti-mitochondrial antibodies (AMA), while liver biochemistry is normal. The silent form is often found in close relatives or patients who underwent an AMA test requested by another specialist. From 70%
to 80% of these patients will develop symptoms of the disease over 20 to 30 years [10, 11] . The asymptomatic form of PBC is characterized by AMA positivity and increase of serum alkaline phosphatase (ALP), although no symptoms are present. Less than 5% of these patients remain asymptomatic over 20 years [12] .
Fatigue and pruritus typically appear in the symptom phase. The symptomatic onset has mainly been noticed in young women affected by most biochemically active forms of disease, less responsive to treatment with UDCA and in whom disease progression was faster [13] .
UDCA is the recommended first-line agent for treatment of PBC, where the optimum dose is 13-15 mg/kg per day [7] . Biochemical response to UDCA in PBC is highly variable among patients. Response rates are lower in male patients and in young women (<45 years old) [14] . An absent or partial response to UDCA is the strongest predictor of poor outcome [14] . [15, 17] .
In addition to UDCA response and histology, the following markers at the time of diagnosis identify patients with a worse prognosis: histological ductopenia, PBC/autoimmune hepatitis overlap syndrome, greater than normal bilirubin levels, low levels of albumin [18, 19] . and the results should be validated over wider geographical regions [20] .
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With regard to serum prognostic markers, an association was described [21, 22] between anti-gp210 positivity and the progression of the disease towards liver failure. Furthermore, in patients presenting anti-centromere antibodies, PBC more often progresses towards portal hypertension. This finding is certainly remarkable, but validation studies in European populations are needed before being able to consider it as a patient stratification criterion.
Diagnosis of PBC: diagnosis of PBC is based on the evidence of persistent
increase of serum ALP in association with AMA positivity.
Currently, most of the patients are diagnosed in the asymptomatic phase of the disease and symptoms generally appear from 2 to 4 years after diagnosis.
The EASL [7] and AASLD [23] guidelines agree on the following PBC diagnostic criteria: At least two of the criteria listed above must be met for the diagnosis of PBC.
Presence of AMA is fundamental, while in case of absence a histologic examination is needed to confirm diagnosis. There is general agreement that AMA stiffness values >9.6 kPa incur major disease-related events over a six year period. During repeated follow up liver stiffness measurements, an increase equal or superior to 2.1 kPa enables to select patients with the highest risk of incurring liver disease-related major events, liver failure, liver transplantation, and death [24] . It must be highlighted, however, that there are currently no data proving the predictive ability of liver stiffness with regard to drug treatment efficacy.
Also the APRI index (AST to Platelet Ratio Index) has been proposed as an independent predictor of advanced fibrosis and worse transplant free survival with cutpoint = 0.54 [25] .
Identification of surrogate markers able to reliably predict the clinical outcome of patients is demanding [26] . Currently, only the serum levels of ALP, both at the time of diagnosis and during treatment with UDCA, are acknowledged as markers of progression. Indeed, there is wide evidence in medical literature that abnormal serum levels of ALP (especially when two times upper normal limit), are predictive of progressive disease [27, 28] . Hyperlipidemia is a common outcome of chronic cholestasis. However, the absence of an additional cardiovascular risk in these patients has been demonstrated [33] . In patients with family history of significant cardiovascular events, or hypercholesterolemia associated with low levels of HDL, lipid lowering drugs should be considered.
Managing cirrhosis. Managing cirrhosis secondary to PBC is not substantially different from managing cirrhosis of other etiology.
Managing cirrhosis due to PBC is not substantially different from managing cirrhosis of other etiology. The incidence of HCC in PBC patients is estimated at 0.36 per 100 person years where male sex, an advanced histologic stage and 14 inadequate response to UDCA being associated with higher risk [34] . In order to monitor the onset of HCC, an ultrasound surveillance every 6 months is required [7] .
In presence of ultrasound signs of portal hypertension, platelet levels <140,000 or
Mayo Risk score >4.1, an endoscopic examination should be performed in order to assess the presence of esophageal varices. [35] . Although the progression of PBC is slow, it is potentially serious: suffice it to mention that the 10 year mortality rate is 59% in PBC patients with greater than normal bilirubin levels and 38% in patients with ALP >2 ULN [37] ; markedly higher with respect to diseases like HCV/HIV coinfection (25%) [38] or mammary carcinoma (29%) [39] . For this reason, it is essential to identify the right treatment capable of blocking the progression of the disease in UDCA non responders or intolerants.
Treating PBC: UDCA is the only drug approved as first line treatment of the disease. Consensus is missing with regard to second line or alternative to UDCA treatments for patients who are non responders or intolerant to this drug. 15 As of today, UDCA is the only drug approved as first line treatment of PBC and the only one recommended by the international guidelines [7, 23] . by a 4 year treatment with UDCA compared to placebo as early as in 1994 [40] .
Following studies demonstrated slower disease progression along with reduced rate of major liver events and need of transplant in patients treated with UDCA compared to control patients [16] . Thus, UDCA is certainly a valid treatment option for patients with PBC; however, in a part of the patient population (around 40%) the drug is ineffective in reducing biochemical markers, ALP in particular.
Furthermore, from 3 to 5% of patients are intolerant to UDCA, manifesting adverse events that prevent continuing the drug, for example incoercible or otherwise unexplained diarrhea.
The definition of UDCA non-responder is not completely clear, as different criteria have been reported in medical literature [41] . These criteria (Table 1) are based on the improvement of biochemical markers of the disease (ALP, gamma-GT, albumin, bilirubin) after 6 to 12 months of treatment. All studies agree that the response to UDCA, whatever the definition, represents an independent prognostic factor of disease progression.
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Therefore, the percentage of patients who are non-responders to UDCA changes according to the chosen marker; by and large, 40% of patients treated with UDCA need an add-on treatment, while 3 to 5% of patients are intolerant to the drug, that is, they manifest adverse events that de facto prevent them from taking it. All models that have been proposed to define the lack of response to UDCA (table 1) are easy to use but also dichotomous, namely they are able to define only two levels of risk (responder and non-responder). Conversely, these models are not With regard to add on therapies to UDCA, according to published studies budesonide and fibrates (bezafibrate, fenofibrate) are of benefit in patients who do not respond to UDCA. However, these are single center or retrospective studies conducted in very small patient populations and requiring validation [44, 45] .
Budesonide might be of more benefit in PBC patients with signs of hepatitis (elevated serum transaminases) in whom the inflammatory component is prevailing, but it cannot be used in patients at cirrhotic stage, with severe osteopenia/osteoporosis, elderly, or who suffer from diabetes or hypertension.
Fibrates might be useful in patients with marked hyperlipidemia and high cardiovascular risk, and in patients with pruritus as a prevailing symptom, but they carry potential side effects like muscle damage (myositis and rhabdomyolysis) and renal insufficiency; fibrates may also cause drug induced liver damage.
As of today, OCA is the only drug for which controlled multicenter studies have demonstrated efficacy in the UDCA non-responder or intolerant patient sub group [46] .
Obeticholic acid (OCA) might be considered as add on therapy in UDCA nonresponders or intolerants.
OCA belongs to the class of bile acids, being an analogue of chenodeoxycholic acid (CDCA), with the addition of an ethyl group providing a strong affinity for the nuclear farnesoid X receptor (FXR). This receptor is involved in the regulation of bile acids homeostasis, inhibiting their production (via the inhibition of CYP7A1 and CYP8A1) [47] , increasing their excretion [48] and reducing liver and intestinal reabsorption [49, 50] . OCA has a 100 times higher affinity for FXR than CDCA, and a different mechanism of action from UDCA, whose primary activity is the dilution of the endogenous bile [51] .
Based on the results of two phase II studies and one phase III study (POISE),
OCA received a conditional approval by EMA [52] . In the phase II 747 202 study, OCA in combination with UDCA was proven to reduce ALP by 20-25% in a non dose-dependent fashion after a 12 week treatment. In these studies the reduction of ALP is clinically and statistically significant as early as after two weeks of treatment, reaches a peak after 6 months and then stabilizes [53] .
The POISE study evaluated a composite primary endpoint recommended by FDA and based on the following elements: ALP<1.67 + ALP reduction of at least by 15% from baseline and total bilirubin (TB) lower than or equal to the Upper Limit of Normal (ULN) at 12 months. The secondary endpoints evaluated were the reductions of biochemical markers: ALP, AST, bilirubin and GGT. The study included three treatment arms: OCA 10mg ± UDCA, Titration (OCA 5mg ± UDCA for 6 months with the OCA dose increased to 10mg for the following 6 months) and placebo ± UDCA. Patients were randomized in 1:1:1 ratio. The primary endpoint was reached by 46 to 47% of patients taking OCA, with an earlier effect in the OCA 10mg treatment arm. OCA was proven effective in reducing ALP, AST and GGT, achieving clinically and statistically significant levels after two weeks of treatment. ALP, AST and GGT reached their lowest levels after three months and then remained stable for the whole study period, as it was seen in phase II studies.
Furthermore, a reduction of ALP by at least 15% was reported in 77% of patients.
Two hundred and sixteen patients, of whom 32 from Italy, were enrolled in the 19 study. The improvement in the markers of cholestasis was also confirmed by the following 12-month open-label phase [46] .
The main adverse event was pruritus, that was the reason for study interruption for 7 out of 73 patients in the OCA 10 mg treatment arm and 1 out of 70 in the titration arm. However, pruritus suffered by patients decreased over time and reached the same level as at baseline after six months [46] . 
Conclusions

